• 1
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(5 Suppl. 1): 237S44S.
  • 2
    Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roel G, BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol 2001; 34: 9116.
  • 3
    Meydani M. Vitamin E. Lancet 1995; 345: 1705.
  • 4
    Dutta A, Dutta SK. Vitamin E and its role in the prevention of atherosclerosis and carcinogenesis: a review. J Am Coll Nutr 2003; 22: 25868.
  • 5
    Westhuyzen J, Saltissi D, Stanbury V. Oxidative stress and erythrocyte integrity in end-stage renal failure patients hemodialyzed using a vitamin E-modified membrane. Ann Clin Lab Sci 2003; 33: 310.
  • 6
    Look MP, Reichel C, Von Falkenhausen M, et al. Vitamin E status in patients with liver cirrhosis: normal or deficient? Metabolism 1999; 48: 869.
  • 7
    Mahmood S, Yamada G, Niyama G, et al. Effect of Vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radical Res 2003; 37: 7815.
  • 8
    Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 166772.
  • 9
    Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo-controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004; 40: 406.
  • 10
    Androne P, Gramonzi A, Bernardi M. Vitamin E for chronic hepatitis B. Ann Int Med 1998; 128: 1567.
  • 11
    Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-a-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterol 1997; 113: 106973.
  • 12
    Brass CA, Piken E. Do antioxidants ameliorate ribavirin related anemia in HCV patients. Gastroenterol 1999; 116: L0056.
  • 13
    Peine CJ, Albrecht JH, Roel JP, Gunderson PA, Kirdner JP, Zins B, Midwest Hepatitis Study Group. Pre-treatment variables that influence health-related quality of life in patients with chronic hepatitis C prior to therapy. Hepatol 2000; 32: 383A.
  • 14
    Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897903.
  • 15
    Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24919.
  • 16
    Ioannou GN, Tung BY, Kowdley KV. Iron in hepatitis C: villain or innocent bystander? Semin Gastrointest Dis 2002; 13: 95108.